Biontech announces positive topline phase 2 results for mrna immunotherapy candidate bnt111 in patients with advanced melanoma

Mainz, germany, july 30, 2024 (globe newswire) --  biontech se (nasdaq: bntx, “biontech” or “the company”) today announced positive topline data from the ongoing phase 2 clinical trial (eudract no.: 2020-002195-12 ; nct04526899 ) in patients with unresectable stage iii or iv melanoma whose disease had progressed following anti-pd-(l)1-containing treatment. the randomized trial evaluates the clinical activity and safety of the investigational mrna cancer immunotherapy bnt111 in combination with libtayo® (cemiplimab), an anti-pd-1 monoclonal antibody being developed by regeneron, and assesses the two single agents alone.
BNTX Ratings Summary
BNTX Quant Ranking